Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My business partner and I have taken positions in SLTD
We like the growth through smart acquisition story, expect 100% or more sales growth in 2015, and will have our investment article out later this week on our site at MicrocapResearch.com
I like those statements from the 10-K.
Originally bought NVIV around a buck/share in December- sold on the run-up, and am buying back here. It's down 27% in a week / oversold. This looks like a great entry, re-entry, or average in price to me.
The reason why 3DP stocks have had such a rough year is due to the crazy year they had in 2013. They were vastly overextended on media hype like "You can 3D print anything you want", etc.
Now these companies are going to trade more based on their fundamentals, which is healthy. The industry itself is growing very rapidly by all indications.... and at some point, these companies will begin to show better performance in share prices based on better quarterly numbers.
Just my opinion-
I think so, yes.
Potential to be bought out or for a JV with a larger player always possible as well in my opinion.
$NVIV down 27% in a week = oversold here IMO.
First bought NVIV at $1.08 and sold at $2.50+. Taking a new position here just above the 50 dma.
I wrote the first to a "commercial scale" launch. GGG has the capacity to do this on a commercial scale that boots industries does not have.
1 Ohm/cm then 10 Ohm/cm resistance sounds good.
Graphene 3D Lab Launches Electrically Conductive Filaments
http://finance.yahoo.com/news/ggg-announces-commercial-sale-conductive-124500750.html
yes- great news! 1st to market with commercial scale electrically conductive filaments.
This is still my No. 1 3D printing stock holding here.
$ZGNX- seems like a no-brainer to me when deal is worth $100M more than the market cap of company and they have two new drugs in development. The market for the Dravat's syndrome drug is tiny, but Relday = huge future market opportunity (if approved).
$ZGNX way oversold. Deal for Zohydro worth $283M w milestones and current market cap of ZGNX < $200M
If the company had no other products in the pipeline I could see the negativity on the sale of Zohydro, but they have Relday which could be a biggie- the first once/month sub-cutaneous injection for schizophrenia. This would help ensure patient compliance in a population well documented to not take meds as prescribed.
http://www.zogenix.com/content/pipeline/relday.htm
Sold my $CAPN starter. Can't pass up a 22% gain in 24 hours in this market.
Looking for next oversold bounce play...
Maybe, but I already sold. In this market, I'll take a 22% gain in 24 hours an day. I think we're going to see a 10% correction to the bull market this spring.
Big difference between growth of an industry vs. corporate income and/or share price.
I was referring to the former.
I'll take a stab at that...
re: "The question was, why are the companies associated with 3-D printing failing to thrive?"
If you look at 3D printing's overall growth as well as sales growth in the individual companies, they are thriving...particularly on the industrial side. Share prices have been hit because the stocks were driven to unrealistic heights during the "hype cycle" of 2013 and still may not be done correcting- especially if we're entering an overall market downturn (which we're overdue for probably).
re: "What is holding back acceptance and sales?" If you're talking consumer grade printers, I think it's the learning curve, need for new, innovative materials, and the still relatively slow speed of 3D printing. It's still a niche market. To cross into mainstream adoption for consumers we need much faster print speeds, true "plug and play" functionality, and better materials (much more than ABS and PLA plastics) to print with.
Just my opinion.
Congrats on the RTI buyout!
Interesting move by AA
Took a starter in $CAPN today.
This one's been on my radar for weeks, so glad to have this pullback to start buying into.
$SSH looking good!
Took a starter in CAPN.
$CTIC- sold. Gap closed and selling increasing.
$CTIC- opening gap closed
Took a starter $2.72
As long as the deaths had nothing to do with the device (which is the case according to the company), then I don't see why it would.
re: "Will it scare patients off from enrolling in trial?"
Yes, but the end result is the same as a traditional intra-aortic baloon pump cath: Decreased afterload (force the heart must work against) and increased pefusion of coronary arteries. But is far less invasive in that the patient can be ambulatory and there isn't a balloon inside their descending aorta.
Would probably become an industry standard if their IABP works without anticoagualtion. Would be in high demand, especially in the immediate post-op setting as a recovery device I'd think.
I don't know.
All I know is in this patient population deaths are going to happen and unless management is lying, the deaths had nothing to do with the device.
I still have to look at their pump to see how it's different/advantageous from competitors- might do that over the weekend if I have time. For now just took a starter here.
True.
But I also have enough business now to be honest
I turned down two nanocaps that wanted a write-up in the last week. BIAD was a rare nanocap exception- most of our stocks are small caps listed on a major exchange.
Besides, most of my articles aren't paid for, and I want to keep it that way. If a really great unknown opportunity (like BIAD) comes along, then I'd consider it.
Short term- I don't care where BIAD goes, except to add to my position if it gets crazy cheap.
Agree it went up to fast...but I think could see .20-.21 as new base before heading higher.
JMO
Long term, we all agree it's a keeper!
Chart looks great and everybody is buying!
And BIAD down 27% in 5 days-
gotta love I-hub, lol.
I buy fear and sell greed- so am perfectly happy about that.
$SSH as a former manager of a cardiovascular surgery ICU, I can see how deaths would be non-device related. Patients requiring an IABP often have multi-system organ involvement and can die from comorbidities. I haven't researched the benefits of this company's device over existing IABP machines, but for SSH to take a 25% or so beating on this news seems overblown.
$SSH beat down to 52 week lows on news that looks like a minor & temporary setback.
Nice bottom fishing play I think
http://finance.yahoo.com/news/sunshine-heart-provides-u-pivotal-103000370.html
Sold for nice ST gain.
Could go to $4, could go to $.40 (if merger doesn't result from LOI).
Good luck all.
Been quiet here lately- but somebody's been buying. GGG.V up nicely in last week while other 3DP stocks continue struggling.
Although it's not much to get excited about I guess since GGG.V is still down from a high of over $2/share. The thing about this stock is that a JV with a large player could send it to new highs overnight IMO.
most 3DP stock charts are really a mess, no doubt.
Bright spot last week or so has been GGG.V / Graphene 3D Lab, which is bumping the 50 dma here. If it breaks thru that, could be a mover.
I'm on that .25 bid now- (just 5K shares) if anybody wants to fill it for me.
Started buying this at .11 and have averaged up since then. BIAD's MIDS market report out this month.
$HOTR a conservative double from here- article
http://microcapresearch.com/chanticleer-holdings/
That site is non-3D printing stocks- mostly biotech.
Hi value1008
My 2 cents is:
-Liquidity will remain pretty healthy going forward due to forward events.
-Yes, I received some $ from BIAD's IR firm for the article. But I've also purchased shares in the open market (as high as .22) and will continue to do so on pullbacks because I personally believe in the company after having spoken with management during my due diligence.
-I can't speak for anyone else, but I'm here for the long haul myself. Will some flip for a quick profit? Absolutely... and there's nothing wrong with that. Some will flip for a penny. Others will flip for a dime, others will hold for a 6-12 month period or more, some might sell half after a nice gain and hold the rest, etc. Everyone's different.
But the bottom line (in my opinion) is that liquidity will remain healthy overall as there are several positive forward events to come, and I also believe the company will be making more of an effort to put out press releases/keep current and new investors aware of progress, etc. This belief is based on the conversation I had with the CEO, Tom Barr. I expect liquidity will remain decent for some time, and unless you're looking to sell in a week, who cares really about liquidity? I'm here for commercialization (via Sysmex, or some other biotech giant) of the COAG and MIDS systems...and that's not going to happen in a week or two anyway.
$BIAD looking like .30s coming next week.
For those new to company, BIAD has the perfect business model- very low cash burn of $70K/month and sits back/collects royalties/licensing fees from multi-billion market cap biotech companies like Sysmex for use of technology that BIAD snatched up for next to nothing out of bankruptcy proceedings.
This is why there's been a lack of dilution in the stock for years, and they have virtually no debt on balance sheet with initial $1M in revenue from Sysmex. That revenue should be recorded in Q1 and is just the start.
This is why BIAD is an investment grade nanocap in my opinion, and it's just beginning to get discovered. The market cap is ridiculous for a biotech company with no dilution, a current ratio of 28 (!) and an agreement with at least one biotech giant.
See current assets vs. current liabilities page 4
https://www.sec.gov/Archives/edgar/data/1370030/000118518514003126/bio-amd10q093014.htm
Then note that revenue is going from "0" in the most recently reported Q to over $1M. When that happens, this board will have hundreds of board marks and BIAD will be discovered. We're in ahead of the market- which is exactly where I like to be!
Thanks hogfan2 for posting!
BIAD is our 2nd biggest winner so far this year.
See Picks and Performance page.
I believe it could ultimately blow past the current % gain in NVIV (now up 170% since our recommendation). Discovery is just beginning.
We're planing to update subscribers with another BIAD report focused on MIDS potential (including quotes from management) in March.
Updated picks/performance on non-3DP stock picks as of 2/27/15
76% average gain from December picks-today.
17% average gain from January picks-today
52% gain in February pick-today
That's measuring from closing price on dates articles published through today, 100% transparent, all winners/green, no hype, no P&D, all with sustained gains.
http://microcapresearch.com/picks-and-performance/
Subscription is FREE
http://microcapresearch.com/subscribe-to-microcapresearch/
$RMTI- back in my buy range now.
Q4 a mixed bag- but many positives, including strong balance sheet/no debt.
"We had a very eventful active year," stated Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell. "Our fourth quarter was exceptional and included three major milestone accomplishments. First, we monetized and de-risked our operating business and positioned it for future growth through our new partnership with Baxter. Then, we conducted a successful FDA advisory committee meeting, achieving a majority vote to approve Triferic as the only iron replacement and hemoglobin maintenance drug for hemodialysis patients. Additionally, we completed a successful financing, strengthening our cash and liquidity position resulting in a strong balance sheet with no debt."
http://finance.yahoo.com/news/rockwell-medical-reports-fourth-quarter-210100140.html